Business Context and Reporting Period
This Form 8-K Current Report was filed by Rocket Pharmaceuticals, Inc. (RCKT) on January 7, 2021, covering events occurring on January 4, 2021. The filing reports significant changes to the company's executive leadership structure, specifically the appointment of a new Chief Financial Officer and the reassignment of the previous Principal Financial Officer.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on personnel changes and compensation arrangements.
Material Changes
- Appointment of CFO: Carlos Garcia-Parada, MBA, joined the company as Chief Financial Officer and Principal Financial Officer.
- Role Reassignment: John Militello, CPA, previously serving as Vice President - Finance, Senior Controller, Treasurer, and Principal Financial and Accounting Officer, will now serve as Vice President - Finance, Senior Controller, Treasurer, and Principal Accounting Officer.
Management Commentary and Compensation Details
The filing details the compensatory arrangements for the new CFO, Mr. Garcia-Parada, under an "at will" employment agreement:
- Base Salary: $410,000 per year.
- Target Bonus: 40% of the annual base salary.
- Equity Grant: A stock option to purchase 125,000 shares of common stock.
- Vesting Schedule: One-third of the option vests on the one-year anniversary of the grant date; the remaining two-thirds vest in eight quarterly increments over the subsequent two years, contingent on continued employment.
- Exercise Price: Equal to the closing price of the company's common stock on the Nasdaq Global Market on the date of grant.
Mr. Garcia-Parada brings extensive experience, having served as Vice President & Finance Head Oncology USA at Novartis International AG since 2011. The filing states there are no related party transactions or family relationships with other officers or directors requiring disclosure.
Investor Verification Checklist
- Verify the exact closing stock price on January 4, 2021, to determine the exercise price of the 125,000 stock options granted to the new CFO.
- Review the full text of the employment agreement, which is referenced as an exhibit to the upcoming Form 10-K for the year ended December 31, 2020.
- Monitor future filings for the impact of the new CFO's strategic direction on the company's financial operations and liquidity.
- Confirm the transition timeline for John Militello's shift from Principal Financial Officer to Principal Accounting Officer.